Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
GlobeNewswire, Inc.
MONTREAL and CHARLOTTE, N.C., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced...
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
GlobeNewswire, Inc.
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed...
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
GlobeNewswire, Inc.
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod...
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
GlobeNewswire, Inc.
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx plans to advance FB102 into...
Nouryon cleared by regulators to supply a plant-based, water-soluble pharmaceutical ingredient in China's expanding drug manufacturing market
GlobeNewswire, Inc.
Global specialty chemicals leader Nouryon today announced the company has received clearance to supply a key pharmaceutical ingredient for medicines made and sold in China, one of the world’s largest drug manufacturing markets.
Cyllene Therapeutics Presents Interim Data from Phase 1b/2a Clinical Trial Showing EG110A Reduced Urinary Episodes in Patients with Spinal Cord Injury at the International Continence Society (ICS) Conference
GlobeNewswire, Inc.
Clinically relevant reduction in urinary incontinence episodes consistently maintained overtime including in the initial set of patients reaching end of study at 52 weeks Treatment was well tolerated, with no serious drug related side effects or...
Nelipak Wins 2026 DuPont™ Tyvek® Sustainable Healthcare Packaging Award for Sustainability In-use
GlobeNewswire, Inc.
CRANSTON, R.I., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nelipak® Corporation (“Nelipak®”), a leading global provider of healthcare packaging solutions, announced it has been named a Dupont™ Tyvek® Sustainable Healthcare Packaging Awards winner in the...
Circle8 Netherlands Signs $492 Million Four-Year Contract Across Three Dutch Government Bodies
GlobeNewswire, Inc.
ENGLEWOOD CLIFFS, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Circle8 Group, Inc. (Nasdaq: CIRC) today announced that its Dutch operating company, Circle8 Netherlands, has signed a four-year contract covering the Dutch Ministry of Health, Welfare and...
Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026
GlobeNewswire, Inc.
MELBOURNE, Australia and OXFORD, United Kingdom, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces it will be...
A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura's roginolisib
GlobeNewswire, Inc.
First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study results, demonstrating...
The success story continues: TGW Logistics increases revenue by 29 percent to 1.55 billion USD
EIN Presswire
Order intake of TGW Logistics, the warehouse automation specialist, reached an all-time high at 1.99 billion USD, while EBIT rose to 61.7 million USD. GRAND RAPIDS, MI, UNITED STATES, October 9, 2026 /EINPresswire.com/ -- TGW Logistics'...
Europe Gift Card Market Companies, Trends and Country Analysis 2026 to 2035: Digital Formats Hold 58.8% and Corporate Buyers 68.1% of Value
GlobeNewswire, Inc.
Ottawa, Oct. 09, 2026 (GLOBE NEWSWIRE) -- The Europe gift card market is valued at USD 81.84 billion in 2026 and is projected to reach USD 155.60 billion by 2035, expanding at a CAGR of 7.4% from 2026 to 2035, according to a new study by...
Core Specialty Affirms AM Best Credit Ratings of Core Specialty Insurance Holdings, Inc. Subsidiaries
GlobeNewswire, Inc.
CINCINNATI, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Affirms the Financial Strength Rating of A (Excellent) for StarStone Specialty Insurance Company, StarStone National Insurance Company, Lancer Insurance Company, Lancer Insurance Company of New Jersey...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire, Inc.
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for...
Amplio Pharma Reports Positive Early Clinical Results for NovoBioJect, Designed to Make the World's Most-Used Rheumatoid Arthritis Drug Work for More Patients
GlobeNewswire, Inc.
A single dose of NovoBioJect increased the active form of methotrexate inside patients' immune cells by 38%, a first step toward a potential next-generation first-line treatment for rheumatoid arthritis First clinical proof of principle.
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
GlobeNewswire, Inc.
WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the final results of its tender...
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
GlobeNewswire, Inc.
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its...
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
GlobeNewswire, Inc.
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression...
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
GlobeNewswire, Inc.
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with...
Medical Devices Market Size to Hit $817.78 Billion by 2031 – MarketsandMarkets™
GlobeNewswire, Inc.
Delray Beach, FL, Sept. 18, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global medical devices market size will grow from USD 580.79 billion in 2026 to USD 817.78 billion by 2031, at a CAGR of 7.1% during the forecast period.
Sign up for:
Healthcare News Netherlands
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.